Table 5.
Potential agents for PSMA-FGS in the preclinical stage
| Year | Country | Institution | Type of ligands | Agents | Aim | In-vivo experiment |
|---|---|---|---|---|---|---|
| 201182 | USA | National Cancer Institute | Humanized Antibody | ICG-huJ591 | FGS | PC3±PSMA |
| 201683 | USA | Johns Hopkins University School of Medicine | Humanized Antibody | J591-IR800 | FGS | PC3±PSMA; LMD±PSMA |
| 201784 | USA | National Cancer Institute | Fully human antibody | Anti-PSMA-IR700 | FGS/PIT | PC3±PSMA |
| 201987 | China | Fourth Military Medical University | Fully human antibody | PSMAb-IRDye800CW | FGS | PC3±PSMA |
| 201688 | China | Fourth Military Medical University | scFv | gy1-IRDye800CW | FGS | PC3±PSMA |
| 201689 | Italy | Verona University | scFv | X770-scFvD2B | FGS | LNCaP |
| 201990 | Netherlands | Radboud university medical center | scFv | 111In-DTPA-D2B-IRDye700DX | FGS/PIT | LS174T±PSMA |
| 201091 | USA | Washington State University | PSMA inhibitor CTT-54.2 | Cy5.5-CTT-54.2 | FGS | LNCaP; PC3 |
| 200992 | USA | Johns Hopkins Medical Institutions | PSMA inhibitor YC-27 3 | YC-27 3-IRDye800CW | FGS | PC3±PSMA |
| 201493 | USA | Case Western Reserve University | PSMA inhibitor PSMA-1 | PSMA-1-IRDye800CW; PSMA-1-Cy5.5 | FGS | PC3±PSMA |
| 201785 | USA | Johns Hopkins Medical Institutions | IRDye700DX | YC-9 | FGS | PC3±PSMA |
| 202086 | Canada | University Health Network | PSMA inhibitor | BPP | FGS | PC3±PSMA |
| 201914 | USA | On Target Laboratories | PSMA inhibitor | OTL78 | FGS | LNCaP;22Rv1; PC3; A549 |
| 201794 | Japan | Yoshida Shimoadachi-cho | PSMA inhibitor | 800CW-SCE | FGS | LNCaP; PC3 |
| 201795 | USA | Massachusetts General Hospital and Harvard Medical School | PSMA inhibitor KUE | ZW800-1 | FGS | LNCaP; PC3 |
| 2018112 | Canada | University Health Network | PSMA inhibitor | 64Cu-LC-Pyro | PET/CT FGS |
PC3±PSMA |
| 202296 | USA | Johns Hopkins Medical Institutions | PSMA inhibitor | DyLight800-10 | FGS | PC3±PSMA |
| 202299 | Germany | German Cancer Research Center (DKFZ) | PSMA inhibitor PSMA-617 | PSMA-927 | FGS | LNCaP; PC3 |
| 2022102 | Netherlands | Radboud University Medical Center | PSMA inhibitor PSMA-N064 | PSMA-N064inc | FGS/PIT | LS174T±PSMA |
| 2022103 | Netherlands | Leiden University Medical Center | PSMA inhibitor EuK | 99mTc-EuK-(SO3)Cy5-mas3 | FGS | Porcine model (15 non-tumor-bearing pigs) |
| 2023105 | China | Peking Union Medical College and Chinese Academy of Medical Sciences | PSMA inhibitor KUE | Cy7 | FGS | C4-2;22RV1; PC3 |
| 2022100 | UK | King's College London | PSMA inhibitor urea-based Glu-Lys | Cy7.5 | FGS | LNCaP; PC3; DU145; DU145 |
| 202397 | China | Northwestern Polytechnical University | PSMA inhibitor Lys-urea-Glu | iridium(III) complex | FGS | LNCaP; 22Rv1; PC3 |
| 2022101 | Italy | University of Torino | PSMA-617 | IRDye700DX | FGS | LNCaP; PC3 |
| 2022104 | Japan | The University of Tokyo | Activatable | 5GluAF-2MeTG | FGS | LNCaP; PC3 |